Suzanne Marie Garland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5683238/publications.pdf

Version: 2024-02-01

314 papers 21,207 citations

23567 58 h-index 137 g-index

322 all docs 322 docs citations

times ranked

322

14002 citing authors

#	Article	IF	CITATIONS
1	Sexual behaviours associated with incident high-risk anal human papillomavirus among gay and bisexual men. Sexually Transmitted Infections, 2022, 98, 101-107.	1.9	8
2	Bacterial biofilm formation on vaginal ring pessaries used for pelvic organ prolapse. International Urogynecology Journal, 2022, 33, 287-295.	1.4	7
3	<i>Chlamydia trachomatis</i> and <i>Mycoplasma genitalium</i> prevalence and associated factors among women presenting to a pregnancy termination and contraception clinic, 2009–2019. Sexually Transmitted Infections, 2022, 98, 115-120.	1.9	6
4	Postnatal Cytomegalovirus Infection of Preterm and Very-low-birth-weight Infants Through Maternal Breast Milk: Does It Matter?. Pediatric Infectious Disease Journal, 2022, 41, 343-351.	2.0	4
5	Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources. Expert Review of Vaccines, 2022, 21, 227-240.	4.4	6
6	HPV prevention and control – The way forward. Preventive Medicine, 2022, 156, 106960.	3.4	15
7	Gene methylation of CADM1 and MAL identified as a biomarker of high grade anal intraepithelial neoplasia. Scientific Reports, 2022, 12, 3565.	3.3	9
8	Random amplified polymorphic DNA analysis reveals no clear link between <i>Staphylococcus epidermidis</i> and acute mastitis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2022, , .	1.0	2
9	Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men. Clinical Infectious Diseases, 2022, 75, 323-329.	5.8	4
10	Impact of 16S rRNA Single Nucleotide Polymorphisms on Mycoplasma genitalium Organism Load with Doxycycline Treatment. Antimicrobial Agents and Chemotherapy, 2022, 66, e0024322.	3.2	3
11	Possible Reactivation of Latent Anal Human Papillomavirus Associated with Markers of Immune Dysfunction in Gay and Bisexual Men. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1052-1057.	2.5	3
12	<i>parC</i> Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure. Antimicrobial Agents and Chemotherapy, 2022, 66, e0027822.	3.2	23
13	The Clinicopathologic Challenge of Nonneoplastic Vulvar Acanthosis. Journal of Lower Genital Tract Disease, 2022, Publish Ahead of Print, .	1.9	O
14	Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women. Tumour Virus Research, 2022, 13, 200236.	3.8	3
15	HIV, Immune Dysfunction, and the Natural History of Anal High-Risk Human Papillomavirus Infection in Gay and Bisexual Men. Journal of Infectious Diseases, 2021, 224, 246-257.	4.0	9
16	The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. Clinical Infectious Diseases, 2021, 72, 853-861.	5.8	40
17	Bone health in young adult survivors born extremely preterm or extremely low birthweight in the post surfactant era. Bone, 2021, 143, 115648.	2.9	9
18	Bone Measures by Dual-Energy X-Ray Absorptiometry and Peripheral Quantitative Computed Tomography in Young Women With Type 1 Diabetes Mellitus. Journal of Clinical Densitometry, 2021, 24, 259-267.	1.2	8

#	Article	IF	CITATIONS
19	Human Papillomavirus Vaccination After COVID-19. JNCI Cancer Spectrum, 2021, 5, pkab011.	2.9	44
20	Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. Preventive Medicine, 2021, 144, 106321.	3.4	12
21	The role of sexually transmitted infections (STI) prevention and control programs in reducing gender, sexual and STI-related stigma. EClinicalMedicine, 2021, 33, 100764.	7.1	10
22	Detection of parC gene mutations associated with quinolone resistance in Mycoplasma genitalium: evaluation of a multiplex real-time PCR assay. Journal of Medical Microbiology, 2021, 70, .	1.8	9
23	Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific. Vaccines, 2021, 9, 921.	4.4	O
24	The effect of probiotic supplementation on the gut microbiota of preterm infants. Journal of Medical Microbiology, 2021, 70, .	1.8	14
25	Human papillomavirus prevalence and risk factors among Australian women 9–12Âyears after vaccine program introduction. Vaccine, 2021, 39, 4856-4863.	3.8	6
26	Prevalence of Mycoplasma genitalium fluoroquinolone-resistance markers, and dual-class-resistance markers, in asymptomatic men who have sex with men. Journal of Medical Microbiology, 2021, 70, .	1.8	12
27	Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Lancet Infectious Diseases, The, 2021, 21, 1448-1457.	9.1	37
28	Evaluation of ResistancePlus MG FleXible, a †near-patient†test for the detection of Mycoplasma genitalium and macrolide resistance mutations, using freshly collected clinical samples. Journal of Medical Microbiology, 2021, 70, .	1.8	5
29	A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis. MBio, 2021, 12, e0232321.	4.1	22
30	The Effect of Exogenous Sex Steroids on the Vaginal Microbiota: A Systematic Review. Frontiers in Cellular and Infection Microbiology, 2021, 11, 732423.	3.9	13
31	Self-reported anal symptoms and their association with anal pathology among gay and bisexual men: a cross-sectional observational analysis. Sexual Health, 2021, 18, 123-129.	0.9	3
32	Accuracy of Self-reported Human Papillomavirus Vaccination Status Among Gay and Bisexual Adolescent Males: Cross-sectional Study. JMIR Public Health and Surveillance, 2021, 7, e32407.	2.6	5
33	Gardnerella vaginalis Clade Distribution Is Associated With Behavioral Practices and Nugent Score in Women Who Have Sex With Women. Journal of Infectious Diseases, 2020, 221, 454-463.	4.0	21
34	Postnatal probiotics and allergic disease in very preterm infants: Subâ€study to the ⟨i⟩ProPrems⟨ i⟩ randomized trial. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 127-136.	5.7	30
35	Clinical Trials of Human Papillomavirus Vaccines. , 2020, , 299-325.		1
36	Twelve Years of Vaccine Registration and the Consequences. , 2020, , 349-361.		0

#	Article	IF	Citations
37	Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Vaccine, 2020, 38, 1186-1193.	3.8	8
38	Associations Between Serum Sodium Concentration and Bone Health Measures in Individuals Who Use Antiepileptic Drugs: A Pilot Study. Journal of Clinical Densitometry, 2020, 23, 364-372.	1.2	2
39	Longâ€ŧerm trends of Chlamydia trachomatis in a clinic population at the Royal Women's Hospital, Melbourne. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 149-153.	1.0	2
40	Prevalence and Association of Perianal and Intra-Anal Warts with Composite High-Grade Squamous Intraepithelial Lesions Among Gay and Bisexual Men: Baseline Data from the Study of the Prevention of Anal Cancer. AIDS Patient Care and STDs, 2020, 34, 436-443.	2.5	9
41	Using Facebook to Improve Participation Among 25-Year-Olds Enrolled in a Longitudinal Preterm Birth Cohort Study. Academic Pediatrics, 2020, 20, 1029-1036.	2.0	3
42	HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. Vaccine, 2020, 38, 6304-6311.	3.8	9
43	Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard. Vaccine, 2020, 38, 6312-6319.	3.8	5
44	Cardiovascular Health Profile at Age 25 Years in Adults Born Extremely Preterm or Extremely Low Birthweight. Hypertension, 2020, 76, 1838-1846.	2.7	21
45	hTERT Protein Expression in Cytoplasm and Nucleus and its Association With HPV Infection in Patients With Cervical Cancer. Cancer Genomics and Proteomics, 2020, 17, 615-625.	2.0	7
46	Human Papillomavirus Genotypes in Anal High-Grade Squamous Intraepithelial Lesion (HSIL): Anal Intraepithelial Neoplasia Grades 2 (AIN2) and 3 (AIN3) Are Different. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2078-2083.	2.5	3
47	Reply to Bourgeois et al., "Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial― MSphere, 2020, 5, .	2.9	1
48	A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine, 2020, 38, 4316-4324.	3.8	16
49	Detection of highâ€grade cervical disease among women referred directly to colposcopy after a positive <scp>HPV</scp> screening test varies with age and cytology findings. International Journal of Cancer, 2020, 147, 3068-3074.	5.1	13
50	Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100202.	4.5	27
51	IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity― Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100195.	4.5	19
52	Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 1302-1314.	9.1	154
53	IPVS Policy Statement addressing the burden of HPV disease for Indigenous peoples. Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100191.	4.5	7
54	Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females. Sexual Health, 2020, 17, 510.	0.9	6

#	Article	IF	CITATIONS
55	Performance of the ResistancePlus MG diagnostic test for Mycoplasma genitalium using samples collected with Hologic Aptima Specimen Collection kits. Journal of Medical Microbiology, 2020, 69, 244-248.	1.8	3
56	A significant measure of HPV vaccine effectiveness in a high-risk population in Korea prior to a National Immunization Program. Journal of Gynecologic Oncology, 2020, 31, e32.	2.2	2
57	Effect of age on the association between recreational drug use and sexual risk behaviour: a cross-sectional observational analysis. Sexual Health, 2020, 17, 538.	0.9	O
58	Estimating the Burden of Illness Related to Genital Warts in Russia: A Cross-Sectional Study. Journal of Health Economics and Outcomes Research, 2020, 7, 182-188.	1.2	1
59	<p>Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus</p> . Infection and Drug Resistance, 2019, Volume 12, 1951-1967.	2.7	47
60	Analysis of Infection Loads in Mycoplasma genitalium Clinical Specimens by Use of a Commercial Diagnostic Test. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
61	HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100175.	4.5	9
62	Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPVâ€16/18 antibodies. Cancer Medicine, 2019, 8, 4938-4953.	2.8	13
63	Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. Expert Review of Vaccines, 2019, 18, 1157-1166.	4.4	21
64	The parC mutation G248T (S83I), and concurrent gyrA mutations, are associated with moxifloxacin and sitafloxacin treatment failure for Mycoplasma genitalium. Journal of Infectious Diseases, 2019, 221, 1017-1024.	4.0	35
65	Multicenter Clinical Evaluation of a Novel Multiplex Real-Time PCR (qPCR) Assay for Detection of Fluoroquinolone Resistance in Mycoplasma genitalium. Journal of Clinical Microbiology, 2019, 57, .	3.9	25
66	Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014–2017. Vaccine, 2019, 37, 6907-6914.	3.8	18
67	Anal human papillomavirus infections in young unvaccinated men who have sex with men attending a sexual health clinic for HPV vaccination in Melbourne, Australia. Vaccine, 2019, 37, 6271-6275.	3.8	10
68	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet, The, 2019, 394, 497-509.	13.7	630
69	Routine cervical screening by primary <scp>HPV</scp> testing: early findings in the renewed National Cervical Screening Program. Medical Journal of Australia, 2019, 211, 113-119.	1.7	39
70	Impact of extreme prematurity or extreme low birth weight on young adult health and well-being: the Victorian Infant Collaborative Study (VICS) 1991–1992 Longitudinal Cohort study protocol. BMJ Open, 2019, 9, e030345.	1.9	19
71	Prevalence, incidence and predictors of anal <i>Chlamydia trachomatis</i> , anal <i>Neisseria gonorrhoeae</i> and syphilis among older gay and bisexual men in the longitudinal Study for the Prevention of Anal Cancer (SPANC). Sexually Transmitted Infections, 2019, 95, 477-483.	1.9	12
72	Compliance with screening for and recommended management of maternal group B streptococcus carriage in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 837-842.	1.0	4

#	Article	IF	CITATIONS
73	Cross-sectional study estimating the psychosocial impact of genital warts and other anogenital diseases in South Korea. BMJ Open, 2019, 9, e025035.	1.9	11
74	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 2019, 152, 465-471.	1.4	14
75	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology, 2019, 154, 110-117.	1.4	62
76	Sexual practices have a significant impact on the vaginal microbiota of women who have sex with women. Scientific Reports, 2019, 9, 19749.	3.3	22
77	Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact. Vaccine, 2019, 37, 412-416.	3.8	35
78	Point-of-care testing and treatment of sexually transmitted infections to improve birth outcomes in high-burden, low-income settings: Study protocol for a cluster randomized crossover trial (the) Tj ETQq0 0 0 rgBT	√ 0. ∞erlock	11 0 3 Tf 50 53
79	Using Mobile Technology to Improve Bone-Related Lifestyle Risk Factors in Young Women With Low Bone Mineral Density: Feasibility Randomized Controlled Trial. JMIR Formative Research, 2019, 3, e9435.	1.4	9
80	Awareness of human papillomavirus, cervical cancer and its prevention among primigravid antenatal clinic attendees in a tertiary care hospital in Sri Lanka: a cross-sectional study. Sexual Health, 2019, 16, 212-217.	0.9	0
81	Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. Journal of Infectious Diseases, 2018, 217, 1590-1600.	4.0	110
82	Laser Microdissection for Human Papillomavirus (HPV) Genotyping Attribution and Methylation Pattern Analyses of Squamous Intraepithelial Lesions. Methods in Molecular Biology, 2018, 1723, 167-189.	0.9	2
83	Associations between 25-hydroxyvitamin D levels, body composition and metabolic profiles in young women. European Journal of Clinical Nutrition, 2018, 72, 1093-1102.	2.9	9
84	Prevalence and Burden Related to Genital Warts in India. Viral Immunology, 2018, 31, 346-351.	1.3	15
85	Human Papillomavirus Seroprevalence and Association with Anal HPV Infection and Squamous Intraepithelial Lesions in Australian Gay and Bisexual Men. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 768-775.	2.5	7
86	Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 134-142.	4.5	49
87	Histological outcomes of anal highâ€grade cytopredictions. Cancer Cytopathology, 2018, 126, 136-144.	2.4	12
88	Polycystic ovarian syndrome: Prevalence and impactÂon the wellbeing of Australian women aged 16–29Âyears. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, 222-233.	1.0	25
89	The role of human papillomavirus in p16â€positive oral cancers. Journal of Oral Pathology and Medicine, 2018, 47, 18-24.	2.7	29
90	Bone turnover marker determinants in young women: results from the Safe-D study. Annals of Clinical Biochemistry, 2018, 55, 328-340.	1.6	5

#	Article	IF	Citations
91	Evaluation of the SpeeDx ResistancePlus MG Diagnostic Test for Mycoplasma genitalium on the Applied Biosystems 7500 Fast Quantitative PCR Platform. Journal of Clinical Microbiology, 2018, 56, .	3.9	14
92	Incorporating digital anorectal examinations for anal cancer screening into routine <scp>HIV</scp> care for men who have sex with men living with <scp>HIV</scp> : a prospective cohort study. Journal of the International AIDS Society, 2018, 21, e25192.	3.0	13
93	Gut microbiota of preterm infants supplemented with probiotics: sub-study of the ProPrems trial. BMC Microbiology, 2018, 18, 184.	3.3	50
94	Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Research (Amsterdam, Netherlands), 2018, 6, 70-76.	4.5	32
95	Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15–26 Years of Age. Obstetrics and Gynecology, 2018, 132, 261-270.	2.4	25
96	Use of Pristinamycin for Macrolide-Resistant <i>Mycoplasma genitalium</i> Infection. Emerging Infectious Diseases, 2018, 24, 328-335.	4.3	58
97	A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. Journal of Infectious Diseases, 2018, 217, 208-212.	4.0	86
98	The new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining quality. Journal of Pathology: Clinical Research, 2018, 4, 207-212.	3.0	7
99	Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine. Open Forum Infectious Diseases, 2018, 5, ofy147.	0.9	7
100	Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine, 2018, 36, 3221-3230.	3.8	43
101	Follow‑up study of HPV58 variants in women with incident HPV58 infection from a Colombian cohort. Oncology Letters, 2018, 16, 2511-2516.	1.8	2
102	Detection of Chlamydia trachomatis mRNA using digital PCR as a more accurate marker of viable organism. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2117-2122.	2.9	11
103	Development of a pilot proficiency program for human papillomavirus DNA detection. Pathology, 2018, 50, 659-664.	0.6	3
104	Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples - A pilot study. PLoS ONE, 2018, 13, e0190199.	2.5	55
105	Development of a rapid colorimetric multiplex PCR–reverse line blot for the detection and typing of 14 Chlamydia trachomatis genovars. Journal of Medical Microbiology, 2018, 67, 1560-1570.	1.8	3
106	Human papillomavirus prevalence in unvaccinated heterosexual males following a national female vaccination program. Journal of Infectious Diseases, 2017, 215, jiw530.	4.0	28
107	Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infectious Diseases, The, 2017, 17, 68-77.	9.1	72
108	Gentamicin in pregnancy: seeing past the drug categorisation in pregnancy. Internal Medicine Journal, 2017, 47, 124-125.	0.8	2

#	Article	IF	CITATIONS
109	Microbial invasion of the amniotic cavity in midtrimester pregnancies using molecular microbiology. American Journal of Obstetrics and Gynecology, 2017, 217, 71.e1-71.e5.	1.3	35
110	What does <i>Chlamydia trachomatis</i> Vetection in a urogenital specimen from a young child mean?. Sexually Transmitted Infections, 2017, 93, 236-237.	1.9	4
111	Manipulating the baby biome: What are the issues?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 232-234.	1.0	1
112	Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 80-84.	4.5	24
113	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 105-115.	4.5	22
114	Genetic and Environmental Factors in Invasive Cervical Cancer: Design and Methods of a Classical Twin Study. Twin Research and Human Genetics, 2017, 20, 10-18.	0.6	11
115	A cross-sectional study estimating the burden of illness related to genital warts in South Korea. BMJ Open, 2017, 7, e014217.	1.9	11
116	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet, The, 2017, 390, 2143-2159.	13.7	314
117	Predictors and correlates of serum 25-hydroxyvitamin D concentrations in young women: results from the Safe-D study. British Journal of Nutrition, 2017, 118, 263-272.	2.3	11
118	Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. International Journal of Cancer, 2017, 141, 1576-1584.	5.1	51
119	HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples. Papillomavirus Research (Amsterdam, Netherlands), 2017, 4, 79-84.	4.5	15
120	Maximizing the Impact of Human Papillomavirus Vaccination. Clinical Infectious Diseases, 2017, 65, 890-892.	5.8	0
121	Serum 25-hydroxyvitamin D and mental health in young Australian women: Results from the Safe-D study. Journal of Affective Disorders, 2017, 224, 48-55.	4.1	11
122	The Association Between Unwanted Sexual Experiences and Early-Onset Cervical Cancer and Precancer by Age 25: A Case–Control Study. Journal of Women's Health, 2017, 26, 774-787.	3.3	7
123	Probiotics, prematurity and neurodevelopment: follow-up of a randomised trial. BMJ Paediatrics Open, 2017, 1, e000176.	1.4	31
124	The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS ONE, 2017, 12, e0171856.	2.5	81
125	UriSwab: an effective transport medium for nucleic acid detection of Chlamydia trachomatis, Mycoplasma genitalium and Neisseria gonorrhoeae. Sexual Health, 2017, 14, 502.	0.9	4
126	Factors associated with unwanted sexual experiences of young Australian females: an observational study. Sexual Health, 2017, 14, 383.	0.9	1

#	Article	IF	CITATIONS
127	Estimating the burden of genital warts in Taiwan. Sexual Health, 2017, 14, 485.	0.9	5
128	Chlamydia Infection Between Men and Women: A Cross-Sectional Study of Heterosexual Partnerships. Open Forum Infectious Diseases, 2017, 4, ofx160.	0.9	8
129	Human papillomavirus vaccination: the population impact. F1000Research, 2017, 6, 866.	1.6	73
130	Comparison of Different Recruitment Methods for Sexual and Reproductive Health Research: Social Media–Based Versus Conventional Methods. Journal of Medical Internet Research, 2017, 19, e73.	4.3	10
131	Using Facebook to Recruit Young Australian Men Into a Cross-Sectional Human Papillomavirus Study. Journal of Medical Internet Research, 2017, 19, e389.	4.3	12
132	Development and Testing of a Mobile Phone App for Self-Monitoring of Calcium Intake in Young Women. JMIR MHealth and UHealth, 2017, 5, e27.	3.7	20
133	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerging Infectious Diseases, 2016, 22, 1732-1740.	4.3	77
134	A novel point-of-care testing strategy for sexually transmitted infections among pregnant women in high-burden settings: results of a feasibility study in Papua New Guinea. BMC Infectious Diseases, 2016, 16, 250.	2.9	52
135	CpG Methylation Analysis of HPV16 in Laser Capture Microdissected Archival Tissue and Whole Tissue Sections from High Grade Anal Squamous Intraepithelial Lesions: A Potential Disease Biomarker. PLoS ONE, 2016, 11, e0160673.	2.5	5
136	Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia. PLoS ONE, 2016, 11, e0161846.	2.5	53
137	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 ASO4-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infectious Diseases, The, 2016, 16, 1154-1168.	9.1	148
138	Detection of <i>Candida </i> spp. in the vagina of a cohort of nulliparous pregnant women by culture and molecular methods: Is there an association between maternal vaginal and infant oral colonisation?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 179-184.	1.0	11
139	Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men. International Journal of Cancer, 2016, 139, 639-646.	5.1	7
140	The performance of anal cytology as a screening test for anal HSILs in homosexual men. Cancer Cytopathology, 2016, 124, 415-424.	2.4	35
141	Sustained antibody responses six years following one, two, or three doses of quadrivalent HPV vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study. Clinical Infectious Diseases, 2016, 64, ciw865.	5.8	25
142	Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences. Journal of Virology, 2016, 90, 5503-5513.	3.4	20
143	Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical Infectious Diseases, 2016, 63, 519-527.	5.8	360
144	Prevalence and risk factors associated with high-grade anal squamous intraepithelial lesions (HSIL)-AIN2 and HSIL-AIN3 in homosexual men. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 97-105.	4. 5	31

#	Article	IF	Citations
145	A Composite Cytology–Histology Endpoint Allows a More Accurate Estimate of Anal High-Grade Squamous Intraepithelial Lesion Prevalence. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1134-1143.	2.5	30
146	Prior human papillomavirusâ€16/18 ASO4â€adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: ⟨i>Postâ€hoc⟨/i> analysis from a randomized controlled trial. International Journal of Cancer, 2016, 139, 2812-2826.	5.1	74
147	Probiotics and mastitis: evidence-based marketing?. International Breastfeeding Journal, 2016, 11, 19.	2.6	46
148	Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics, 2016, 138, .	2.1	84
149	<i>Chlamydia trachomatis</i> genotypes in a cross-sectional study of urogenital samples from remote Northern and Central Australia. BMJ Open, 2016, 6, e009624.	1.9	18
150	Baseline findings from the Anal Cancer Examination (ACE) study: screening using digital ano-rectal examination in HIV-positive men who have sex with men. Journal of Medical Screening, 2016, 23, 70-76.	2.3	18
151	Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 61-69.	4.5	30
152	Is there a role for the thinprep imaging system in reporting anal cytology?. Diagnostic Cytopathology, 2016, 44, 384-388.	1.0	O
153	Clinicians' attitude towards changes in Australian National Cervical Screening Program. Journal of Clinical Virology, 2016, 76, S81-S87.	3.1	10
154	Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. International Journal of Cancer, 2016, 138, 2428-2438.	5.1	80
155	Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16–28 years. Journal of Clinical Virology, 2016, 76, S74-S80.	3.1	26
156	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	27.6	154
157	Anal HPV detection in men who have sex with men living with HIV who report no recent anal sexual behaviours: baseline analysis of the Anal Cancer Examination (ACE) study. Sexually Transmitted Infections, 2016, 92, 368-370.	1.9	16
158	Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology. PLoS ONE, 2016, 11, e0156740.	2.5	67
159	Guidelines and Recommendations for Developing Interactive eHealth Apps for Complex Messaging in Health Promotion. JMIR MHealth and UHealth, 2016, 4, e14.	3.7	45
160	Improving Vitamin D Status and Related Health in Young Women: The Safe-D study – Part B. JMIR Research Protocols, 2016, 5, e80.	1.0	4
161	Targeted Facebook Advertising is a Novel and Effective Method of Recruiting Participants into a Human Papillomavirus Vaccine Effectiveness Study. JMIR Research Protocols, 2016, 5, e154.	1.0	35
162	An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. Pediatric Infectious Disease Journal, 2015, 34, 983-991.	2.0	103

#	Article	IF	CITATIONS
163	The problem of late ovarian metastases from primary cervical adenocarcinoma. Gynecologic Oncology Reports, 2015, 13, 23-25.	0.6	6
164	Estimation of Cancer Burden Attributable to Infection in Asia. Journal of Epidemiology, 2015, 25, 626-638.	2.4	18
165	Exposing the gaps in awareness, knowledge and estimation of risk for anal cancer in men who have sex with men living with HIV: a crossâ€sectional survey in Australia. Journal of the International AIDS Society, 2015, 18, 19895.	3.0	13
166	Determinants of mastitis in women in the CASTLE study: a cohort study. BMC Family Practice, 2015, 16, 181.	2.9	50
167	HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents. BMC Public Health, 2015, 15, 896.	2.9	17
168	Vitamin D Status, Bone Mineral Density and Mental Health in Young Australian Women: The Safe-D Study. Journal of Public Health Research, 2015, 4, jphr.2015.594.	1.2	22
169	Human papillomavirus prevalence to age 60 years among Australian women prevaccination. Sexual Health, 2015, 12, 353.	0.9	9
170	Efficacy of fewer than three doses of an HPV-16/18 ASO4-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncology, The, 2015, 16, 775-786.	10.7	247
171	Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions. BMJ Open, 2015, 5, e008439.	1.9	19
172	HPV vaccination for victims of childhood sexual abuse. Lancet, The, 2015, 386, 1919-1920.	13.7	11
173	In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: Implications for post-vaccine surveillance studies. Journal of Virological Methods, 2015, 214, 10-14.	2.1	11
174	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine, 2015, 372, 711-723.	27.0	1,090
175	Asking about human papillomavirus vaccination and the usefulness of registry validation: A study of young women recruited using Facebook. Vaccine, 2015, 33, 826-831.	3.8	16
176	Macrolide Resistance and Azithromycin Failure in a Mycoplasma genitalium-Infected Cohort and Response of Azithromycin Failures to Alternative Antibiotic Regimens. Clinical Infectious Diseases, 2015, 60, 1228-1236.	5.8	150
177	Dual Intervention to Increase Chlamydia Retesting. American Journal of Preventive Medicine, 2015, 49, 1-11.	3.0	28
178	Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) ASO4-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. Vaccine Journal, 2015, 22, 361-373.	3.1	89
179	Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine, 2015, 33, 6855-6864.	3.8	67
180	Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infectious Diseases, The, 2015, 15, 1314-1323.	9.1	56

#	Article	IF	CITATIONS
181	Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine, 2015, 33, 5042-5050.	3.8	16
182	Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 65-73.	9.1	40
183	Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine, 2015, 33, 201-208.	3.8	51
184	Comparison of the Roche Cobas® 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia. Journal of Clinical Virology, 2015, 62, 63-65.	3.1	23
185	Basal Temperature Measurement Using a Multi-Sensor Armband in Australian Young Women: A Comparative Observational Study. JMIR MHealth and UHealth, 2015, 3, e94.	3.7	5
186	A Comparison of Self-Reported and Objective Physical Activity Measures in Young Australian Women. JMIR Public Health and Surveillance, 2015 , 1 , $e14$.	2.6	21
187	Detection of Oral Human Papillomavirus in HIV-Positive Men Who Have Sex with Men 3 Years after Baseline: A Follow Up Cross-Sectional Study. PLoS ONE, 2014, 9, e102138.	2.5	21
188	A Case-Control Study of the Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma in Australia. Journal of Oncology, 2014, 2014, 1-7.	1.3	6
189	Genital warts. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 1063-1073.	2.8	47
190	Web-based Recruiting for a Survey on Knowledge and Awareness of Cervical Cancer Prevention Among Young Women Living in Kanagawa Prefecture, Japan. International Journal of Gynecological Cancer, 2014, 24, 1347-1355.	2.5	25
191	Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. Journal of Infectious Diseases, 2014, 210, 517-534.	4.0	45
192	Question 2: Which infants with congenital cytomegalovirus infection benefit from antiviral therapy?. Archives of Disease in Childhood, 2014, 99, 597-601.	1.9	6
193	Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. International Journal of Cancer, 2014, 135, 996-1001.	5.1	42
194	Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infectious Diseases, 2014, 14, 551.	2.9	32
195	The Australian Experience With the Human Papillomavirus Vaccine. Clinical Therapeutics, 2014, 36, 17-23.	2.5	73
196	Improving Oral Human Papillomavirus Detection Using Toothbrush Sampling in HIV-Positive Men Who Have Sex with Men. Journal of Clinical Microbiology, 2014, 52, 2206-2209.	3.9	11
197	HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. Journal of Clinical Virology, 2014, 60, 250-256.	3.1	31
198	Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. Expert Opinion on Biological Therapy, 2014, 14, 527-534.	3.1	5

#	Article	IF	CITATIONS
199	Genital herpes. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 1098-1110.	2.8	68
200	Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infectious Diseases, The, 2014, 14, 958-966.	9.1	243
201	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 ASO4-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet, The, 2014, 384, 2213-2227.	13.7	153
202	Early Acquisition of Anogenital Human Papillomavirus Among Teenage Men Who Have Sex With Men. Journal of Infectious Diseases, 2014, 209, 642-651.	4.0	57
203	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1997-2008.	2.5	137
204	Evaluation of an automated SPF10-LiPA25 assay for detection and typing of human papillomavirus in archival samples. Journal of Virological Methods, 2014, 199, 116-118.	2.1	4
205	Sexual Behaviors and Risk for Sexually Transmitted Infections Among Teenage Men Who Have Sex With Men. Journal of Adolescent Health, 2014, 55, 247-253.	2.5	20
206	Global Genomic Diversity of Human Papillomavirus 6 Based on 724 Isolates and 190 Complete Genome Sequences. Journal of Virology, 2014, 88, 7307-7316.	3.4	33
207	How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions. Vaccine, 2014, 32, 4082-4088.	3.8	15
208	How very young men who have sex with men view vaccination against human papillomavirus. Vaccine, 2014, 32, 3936-3941.	3.8	28
209	Rapid assay to assess colonization patterns following in-vivo probiotic ingestion. BMC Research Notes, 2013, 6, 252.	1.4	11
210	The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models. BMC Infectious Diseases, 2013, 13, 83.	2.9	1
211	Anal and perianal squamous carcinomas and highâ€grade intraepithelial lesions exclusively associated with "lowâ€risk‷HPV genotypes 6 and 11. International Journal of Cancer, 2013, 133, 2253-2258.	5.1	76
212	Human papillomavirus types 6 and 11 seropositivity: Risk factors and association with ano-genital warts among homosexual men. Journal of Infection, 2013, 66, 503-511.	3.3	9
213	The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study. BMC Public Health, 2013, 13, 946.	2.9	83
214	Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer, 2013, 13, 296.	2.6	20
215	Does <i>Candida</i> and/or <i>Staphylococcus</i> play a role in nipple and breast pain in lactation? A cohort study in Melbourne, Australia. BMJ Open, 2013, 3, e002351.	1.9	47
216	Role of human papillomaviruses in esophageal squamous cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 12-28.	1.1	27

#	Article	IF	Citations
217	Human papillomavirus in adolescents: Lessons learned from decades of evaluation. Journal of Paediatrics and Child Health, 2013, 49, 99-104.	0.8	6
218	Extended Middle East and North Africa: Summary Recommendations for the Prevention of Human Papillomavirus Infections and Related Cancers Including Cervical Cancer. Vaccine, 2013, 31, G78-G79.	3.8	2
219	Probiotic Effects on Late-onset Sepsis in Very Preterm Infants: A Randomized Controlled Trial. Pediatrics, 2013, 132, 1055-1062.	2.1	255
220	Attitudes to chlamydia screening elicited using the social networking site Facebook for subject recruitment. Sexual Health, 2013, 10, 224.	0.9	25
221	Efficacy of the HPV-16/18 ASO4-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized) Tj ETQq1	4.8.7843	14 rgBT /○√
222	Hybrid Capture II Testing for High-Risk Human Papillomavirus DNA in the Follow-up of Women Treated for High-Grade Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 2013, 17, 308-314.	1.9	5
223	Knowledge of human papillomavirus and cervical cancer among young women recruited using a social networking site: TableÂ1. Sexually Transmitted Infections, 2013, 89, 327-329.	1.9	30
224	Human Papillomavirus Type 6 and 11 Genetic Variants Found in 71 Oral and Anogenital Epithelial Samples from Australia. PLoS ONE, 2013, 8, e63892.	2.5	23
225	Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. PLoS ONE, 2013, 8, e79260.	2.5	101
226	Cervical Cancer Burden and Prevention Strategies: Asia Oceania Perspective. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1414-1422.	2.5	23
227	Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiology, 2012, 7, 193-199.	2.0	14
228	Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ: British Medical Journal, 2012, 344, e1401-e1401.	2.3	244
229	Fall in Human Papillomavirus Prevalence Following a National Vaccination Program. Journal of Infectious Diseases, 2012, 206, 1645-1651.	4.0	218
230	Probiotics in neonatology. Journal of Paediatrics and Child Health, 2012, 48, 777-783.	0.8	29
231	Overall efficacy of HPV-16/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 89-99.	10.7	584
232	Cross-protective efficacy of HPV-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 100-110.	10.7	432
233	Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncology, The, 2012, 13, 487-500.	10.7	806
234	Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecologic Oncology, 2012, 127, 440-450.	1.4	55

#	Article	IF	Citations
235	Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence. BMC Infectious Diseases, 2012, 12, 243.	2.9	14
236	The prevalence of anal human papillomavirus among young HIV negative men who have sex with men. BMC Infectious Diseases, 2012, 12, 341.	2.9	11
237	Premenstrual vaginal colonization of Candida and symptoms of vaginitis. Journal of Medical Microbiology, 2012, 61, 1580-1583.	1.8	5
238	A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine, 2012, 30, F123-F138.	3.8	610
239	Chlamydia trachomatis Incidence and Re-Infection among Young Women – Behavioural and Microbiological Characteristics. PLoS ONE, 2012, 7, e37778.	2.5	102
240	Web-Based Recruiting for Health Research Using a Social Networking Site: An Exploratory Study. Journal of Medical Internet Research, 2012, 14, e20.	4.3	345
241	Distribution of human papillomavirus genotypes in archival cervical tissue from women with cervical cancer in urban Sri Lanka. International Journal of Gynecology and Obstetrics, 2011, 115, 180-182.	2.3	5
242	Assessment of first sexual intercourse in young women with a history of childhood sexual abuse. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2011, 51, 276-279.	1.0	2
243	Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Preventive Medicine, 2011, 53, S29-S35.	3.4	69
244	Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Medicine, 2011, 9, 104.	5.5	66
245	Coagulase-Negative Staphylococci in Low Birth Weight Infants: Environmental Factors Affecting Biofilm Production in Staphylococcus epidermidis. Current Microbiology, 2011, 62, 850-854.	2.2	9
246	The ProPrems trial: investigating the effects of probiotics on late onset sepsis in very preterm infants. BMC Infectious Diseases, 2011, 11, 210.	2.9	47
247	The role of micro-organisms (Staphylococcus aureus and Candida albicans) in the pathogenesis of breast pain and infection in lactating women: study protocol. BMC Pregnancy and Childbirth, 2011, 11, 54.	2.4	25
248	Impact of an HPV6/11/16/18 L1 virusâ€like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. International Journal of Cancer, 2011, 129, 2632-2642.	5.1	47
249	Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji. Sexual Health, 2011, 8, 338.	0.9	12
250	Asia Oceania Guidelines for the Implementation of Programs for Cervical Cancer Prevention and Control. Journal of Cancer Epidemiology, 2011, 2011, 1-24.	1.1	17
251	Clearance of Human Papillomavirus in Women Treated for Cervical Dysplasia. Obstetrics and Gynecology, 2011, 117, 101-108.	2.4	18
252	Antimicrobial resistance in group B streptococcus: the Australian experience. Journal of Medical Microbiology, 2011, 60, 230-235.	1.8	36

#	Article	IF	CITATIONS
253	Comparison of Two Mycoplasma genitalium Real-Time PCR Detection Methodologies. Journal of Clinical Microbiology, 2011, 49, 1140-1142.	3.9	33
254	Mucosal Immunity in Sexually Transmitted Infections. , 2011, , 49-73.		1
255	Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sexual Health, 2010, 7, 310.	0.9	40
256	Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia's role. Sexual Health, 2010, 7, 227.	0.9	1
257	Prevention strategies against human papillomavirus in males. Gynecologic Oncology, 2010, 117, S20-S25.	1.4	20
258	A Cautionary Note on Instituting Probiotics Into Routine Clinical Care for Premature Infants. Pediatrics, 2010, 126, e741-e742.	2.1	16
259	Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ: British Medical Journal, 2010, 341, c3493-c3493.	2.3	323
260	Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. Journal of the National Cancer Institute, 2010, 102, 325-339.	6.3	493
261	Human Papillomavirus Vaccines. Drugs, 2010, 70, 1079-1098.	10.9	123
262	Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology, The, 2010, 11, 1048-1056.	10.7	2,093
263	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virusâ€Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPVâ€Naive Women Aged 16–26 Years. Journal of Infectious Diseases, 2009, 199, 926-935.	4.0	528
264	A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types) Tj ETQq0 0 0 Research, 2009, 2, 868-878.	rgBT /Ove	erlock 10 Tf 5 272
265	Human Papillomavirus Infections and Vulvar Disease Development. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1777-1784.	2.5	45
266	Evaluation of quadrivalent HPV $6/11/16/18$ vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin, 2009, 5, 696-704.	2.4	184
267	HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. Journal of Medical Virology, 2009, 81, 1283-1291.	5.0	35
268	Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far. Vaccine, 2009, 27, 7270-7281.	3.8	67
269	Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. Journal of Infectious Diseases, 2009, 199, 805-814.	4.0	436
270	Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine. Obstetrics and Gynecology, 2009, 114, 1179-1188.	2.4	104

#	Article	IF	CITATIONS
271	Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian Journal of Medical Research, 2009, 130, 311-21.	1.0	9
272	Prevalence of HSV-2 antibody in a Melbourne antenatal population attending a tertiary obstetric hospital. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 266-272.	1.0	9
273	Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler® 480 system. Journal of Virological Methods, 2008, 147, 290-296.	2.1	51
274	Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and Prevention. Vaccine, 2008, 26, M80-M88.	3.8	47
275	Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada and Australia. Vaccine, 2008, 26, K68-K75.	3.8	47
276	Recommendations for Cervical Cancer Prevention in Asia Pacific. Vaccine, 2008, 26, M89-M98.	3.8	41
277	HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine, 2008, 26, 6844-6851.	3.8	168
278	Validation of an Automated Detection Platform for Use with the Roche Linear Array Human Papillomavirus Genotyping Test. Journal of Clinical Microbiology, 2008, 46, 3813-3816.	3.9	29
279	Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results. Journal of Clinical Microbiology, 2007, 45, 2130-2137.	3.9	77
280	Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines. Vaccine Journal, 2007, 14, 792-795.	3.1	35
281	Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria, Australia. Sexual Health, 2007, 4, 177.	0.9	62
282	Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, The, 2007, 369, 1693-1702.	13.7	579
283	Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine, 2007, 356, 1928-1943.	27.0	1,741
284	A case-control study of mastitis: nasal carriage of Staphylococcus aureus. BMC Family Practice, 2006, 7, 57.	2.9	32
285	Cosmetic tattooing: A potential transmission route for HIV?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 458-459.	1.0	5
286	Human papillomavirus genotyping using a modified linear array detection protocol. Journal of Virological Methods, 2006, 135, 124-126.	2.1	35
287	Assessment of MagNA Pure LC Extraction System for Detection of Human Papillomavirus (HPV) DNA in PreservCyt Samples by the Roche AMPLICOR and LINEAR ARRAY HPV Tests. Journal of Clinical Microbiology, 2006, 44, 2428-2433.	3.9	53
288	HPV DNA testing: Potential clinical applications. International Journal of Health Promotion and Education, 2006, 44, 107-112.	0.9	3

#	Article	IF	CITATIONS
289	Evaluation of a Modified Reverse Line Blot Assay for Detection and Typing of Human Papillomavirus. American Journal of Clinical Pathology, 2005, 123, 896-899.	0.7	31
290	Diagnosis of sexually transmitted infections (STI) using self-collected non-invasive specimens. Sexual Health, 2004, 1, 121.	0.9	42
291	Imiquimod. Current Opinion in Infectious Diseases, 2003, 16, 85-89.	3.1	86
292	Reappraisal of C-reactive protein as a screening tool for neonatal sepsis. Pathology, 2003, 35, 240-243.	0.6	19
293	Can we really beat cervical cancer?. Medical Journal of Australia, 2003, 178, 647-650.	1.7	9
294	Prevalence of Sexually Transmitted Infections (Neisseria gonorrhoeae, Chlamydia trachomatis,) Tj ETQq0 0 0 rgBT Diseases Clinic in Ulaanbaatar, Mongolia. Infectious Diseases in Obstetrics and Gynecology, 2001, 9, 143-146.		10 Tf 50 55 36
295	Is antenatal group B streptococcal carriage a predictor of adverse obstetric outcome?. Infectious Diseases in Obstetrics and Gynecology, 2000, 8, 138-142.	1.5	11
296	Homeless young people: an important risk group for sexually transmitted infections. Medical Journal of Australia, 2000, 172, 244-244.	1.7	5
297	Juvenile Laryngeal Papillomatosis in a Pediatric Population: A Clinicopathologic Study. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 53-64.	0.3	23
298	JUVENILE LARYNGEAL PAPILLOMATOSIS IN A PEDIATRIC POPULATION: A Clinicopathologic Study. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 53-64.	0.3	8
299	Is cryotherapy treating or infecting?. Medical Journal of Australia, 1996, 164, 263-264.	1.7	7
300	Prevention of infection in obstetric and gynecological ultrasound practice. Ultrasound in Obstetrics and Gynecology, 1996, 7, 1-4.	1.7	11
301	Role of genital mycoplasmas in bacteremia: Should we be routinely culturing for these organisms?. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 329-332.	1.5	0
302	Earlyâ€onset neonatal group B streptococcal sepsis: economics of various prevention strategies. Medical Journal of Australia, 1995, 162, 413-417.	1.7	37
303	Squamous Cell Carcinoma of the Tongue in a Child with Fanconi Anemia: A Case Report and Review of the Literature. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1995, 15, 597-607.	0.3	26
304	Prevention of Neonatal Group B Streptococcal Sepsis: Is Routine Antenatal Screening Appropriate. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 120-126.	1.0	30
305	A Cohort Study Comparing the Detection of HPV DNA from Women Who Stop and Continue to Smoke. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 181-185.	1.0	7
306	A Pain in the Neck in Pregnancy: Cervical Spinal Tuberculosis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 398-400.	1.0	6

#	Article	IF	CITATIONS
307	Management Guidelines for M. Tuberculosis in Pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1995, 35, 401-405.	1.0	3
308	The Risks and Benefits of Antimicrobial Therapy in Pregnancy. Drug Safety, 1995, 13, 188-205.	3.2	23
309	Human papillomavirus vulvitis: a new disease or an unfortunate mistake?. BJOG: an International Journal of Obstetrics and Gynaecology, 1994, 101, 992-998.	2.3	29
310	Is HPV always sexually acquired?. Medical Journal of Australia, 1993, 159, 724-726.	1.7	4
311	GenitalChlamydia trachomatisinfection in Australia. Medical Journal of Australia, 1993, 159, 90-96.	1.7	24
312	The Absence of Genital Human Papillomavirus DNA in Virginal Women. International Journal of STD and AIDS, 1992, 3, 414-417.	1.1	50
313	Postabortal Pelvic Sepsis in Association with Chlamydia Trachomatis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1990, 30, 347-350.	1.0	18
314	Chlamydia trachomatis infections â€" The Royal Women's Hospital experience. Medical Journal of Australia, 1989, 150, 174-177.	1.7	12